Sight Sciences : Investor Presentation - Jan 2023

™

Delivering the

Power of Sight

Investor Presentation

January 2023

1

Forward-Looking Statements

This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and

uncertainties. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact, including statements regarding These forward-looking statements include, but are not limited to, statements concerning the following: estimates of the Company's total addressable market; the Company's ability to enter into and compete in new markets; the Company's ability to compete effectively with existing competitors and new market entrants; the Company's ability to scale our infrastructure; the Company's ability to manage and grow its business by expanding our sales to existing customers or introducing our products to new customers; the Company's ability to obtain and

maintain regulatory approvals and clearances for its products that support its revenue projections, business strategies and growth; the Company's ability to successfully execute its clinical trial roadmap; and the Company's ability to obtain and maintain sufficient reimbursement for its products. These statements often include words such as "anticipate,"

"expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions. Management

bases these forward-looking statements on its current expectations, plans and assumptions affecting the Company's business and industry, and such statements are based on information available as of the time such statements are made. Although management believes these forward-looking statements are based upon reasonable assumptions, it cannot guarantee their accuracy or completeness. Forward-looking statements are subject to and involve risks, uncertainties and assumptions that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance, or achievements predicted, assumed or implied by such forward-looking statements. Some of the risks and uncertainties that may cause actual results to materially differ from those expressed or implied by these forward-looking statements are discussed under the

caption "Risk Factors" in the Company's filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this press release. We undertake no obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own estimates and research are reliable, such estimates and research have not been verified by any independent source.

We have proprietary rights to trademarks, trade names and service marks appearing in this presentation that are important to our business. Solely for convenience, the trademarks, trade names and service marks may appear in this presentation without the ® and ™ symbols, but any such references are not intended to indicate, in any way, that we forgo or will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Without limitation, SIGHT SCIENCES™, OMNI®, SION™ and TEARCARE® are trademarks of Sight Sciences, Inc. in the United States and other countries.

2

Our Mission

Transform Ophthalmology and Optometry through products that target the underlying causes of the world's most prevalent eye diseases

Establish new treatment paradigms and create an interventional mindset in Eyecare to replace conventional outdated approaches

Goal: Products that Restore Natural Functionality of Diseased Eyes to Deliver Consistent, Effective and Safe Outcomes for Patients

3

Surgical Glaucoma

Dry Eye

CURRENT PRODUCT PORTFOLIO

3.4M	$6Bn	>130k	14M	$10Bn	>20k
Diagnosed		Cases	Evaporative		Cases
U.S. TAM	DED diagnosed	U.S. TAM
U.S. patients	Performed1	U.S. patients	Performed1

• Glaucoma is #1 cause of irreversible blindness
• Microinvasive Glaucoma Surgery (MIGS) is the leading innovation in primary open-angle glaucoma (POAG) treatment
• Underdeveloped Standalone MIGS segment represents $5 billion U.S. market opportunity
• OMNI® indicated to treat all severities of POAG in adults with or without concomitant cataract surgery
• Introduced innovative SION™ Surgical Instrument for bladeless goniotomy 3Q2022

• Increasing dry eye disease (DED) prevalence linked to many prominent demographic, medical and sociological trends
• Meibomian gland disease (MGD) is associated with 86% of DED cases but severely undertreated in current DED practice
• Massive need for patient access to effective MGD treatments
• TearCare® indicated for patients with evaporative DED due to MGD

Additional products in development to build comprehensive portfolio of POAG and DED treatment options

1.As of September 30, 2022.

4

Strategic Value-Creation Initiatives

Expand Presence in Established	Develop and Grow Underserved
Combination Cataract MIGS
Standalone MIGS Segment in POAG
Segment in POAG

Develop Market Access for

TearCare® Procedures

••Continue gaining adoption among existing base of >5,600 MIGS-trained surgeons

••Continue penetrating Combination

Cataract segment by leveraging superior efficacy of OMNI®

••Establish SION as best-in-class goniotomy device among targeted customer subsets

••More established market with compelling growth : $1BN U.S. TAM, ~1/3 penetrated

••Significant untapped opportunity in 5x larger Standalone MIGS segment

••Enable surgeons to intervene earlier in disease progression with minimally invasive procedure, treating patients not requiring cataract surgery

••Expand use by existing OMNI-trained surgeons from Combination Cataract cases to Standalone cases

••Educate POAG community regarding earlier potential Standalone interventions, help connect with OMNI-trained surgeons

••Long term strategy with multiple complementary elements

••SAHARA RCT versus Restasis® - designed with input from eight payor medical directors to demonstrate effectiveness and durability

••Increase real-world usage and claims submissions

••December 2021 FDA clearance expanded indication for use

••Convert existing Category III CPT code (0563T) to permanent Category I code

Bedrock of Clinical Excellence: numerous completed, ongoing and planned trials in POAG and DED